The Bratislava-based company SanaClis has been operating for several years as an important link in the international drug research and development chain. For pharmaceutical companies from all over the world, it ensures the implementation of clinical trials of developed and new drugs.
The year 2024 was a successful one for the company, with sales up almost 25% and net profit almost doubling year-on-year. In 2025, SanaClis expects further revenue growth of 15% to 20%.
The company started in Slovakia, gradually expanded to the region and then to global markets, where it now operates approximately twenty branches. By the end of the year, it plans to open new offices in Latin America and the European Union.
SanaClis employs approximately 300 people globally, of which about 80 are based in Slovakia. It also collaborates with external experts in more than 20 countries, enabling it to provide clinical trials in a large international network. Almost all of the Slovak branch’s revenues come from foreign contracts. Thanks to this export focus, SanaClis was nominated for the TREND Exporter of the Year 2025 award.
The partner of this category of the annual TREND TOP awards is Eximbanka.
Source: TREND.sk